Robert T Martin1, John Whyte. 1. Moss Rehabilitation Research Institute, Albert Einstein Healthcare Network, Philadelphia, Pennsylvania 19141, USA.
Abstract
OBJECTIVE: To determine the effects of methylphenidate (MPH) on command following and yes/no communication in brain injured patients with severe disorders of consciousness (DOC). DESIGN: A meta-analysis of a series of single-subject repeated crossover trials, using doses ranging from 7.5 to 25 mg (median dose: 10 mg), generally given twice a day. A Wilcoxon signed ranks test was performed, comparing mean responsiveness and accuracy by drug condition. Drug effect sizes were calculated for the full group and for participant subgroups of interest. RESULTS: No significant effect of MPH was seen on either responsiveness or on accuracy in the whole group. None of the patient subgroups examined showed a substantial drug effect size. CONCLUSIONS: This study did not identify a clinically meaningful effect of MPH in the doses used on responsiveness or accuracy in standardized command-following protocols in the overall study group of patients with severe DOC, or in any subgroup that was assessed. Because MPH has been shown to have some positive effects in higher-level patients with TBI, more research is needed to define the types of individuals with TBI who do and do not benefit from this drug, and/or the dose that provides optimal benefit.
OBJECTIVE: To determine the effects of methylphenidate (MPH) on command following and yes/no communication in brain injured patients with severe disorders of consciousness (DOC). DESIGN: A meta-analysis of a series of single-subject repeated crossover trials, using doses ranging from 7.5 to 25 mg (median dose: 10 mg), generally given twice a day. A Wilcoxon signed ranks test was performed, comparing mean responsiveness and accuracy by drug condition. Drug effect sizes were calculated for the full group and for participant subgroups of interest. RESULTS: No significant effect of MPH was seen on either responsiveness or on accuracy in the whole group. None of the patient subgroups examined showed a substantial drug effect size. CONCLUSIONS: This study did not identify a clinically meaningful effect of MPH in the doses used on responsiveness or accuracy in standardized command-following protocols in the overall study group of patients with severe DOC, or in any subgroup that was assessed. Because MPH has been shown to have some positive effects in higher-level patients with TBI, more research is needed to define the types of individuals with TBI who do and do not benefit from this drug, and/or the dose that provides optimal benefit.
Authors: Elizabeth O Lillie; Bradley Patay; Joel Diamant; Brian Issell; Eric J Topol; Nicholas J Schork Journal: Per Med Date: 2011-03 Impact factor: 2.512
Authors: Brian L Edlow; Leandro R D Sanz; Robert D Stevens; Olivia Gosseries; Len Polizzotto; Nader Pouratian; John D Rolston; Samuel B Snider; Aurore Thibaut Journal: Neurocrit Care Date: 2021-07-08 Impact factor: 3.210
Authors: Lennart R B Spindler; Andrea I Luppi; Ram M Adapa; Michael M Craig; Peter Coppola; Alexander R D Peattie; Anne E Manktelow; Paola Finoia; Barbara J Sahakian; Guy B Williams; Judith Allanson; John D Pickard; David K Menon; Emmanuel A Stamatakis Journal: Proc Natl Acad Sci U S A Date: 2021-07-27 Impact factor: 12.779